Climb Bio, Inc. (CLYM) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-02-27

Key Insights

The reporting person, Thomas Stephen Basil, who is a director of Climb Bio, Inc., has reported the sale of a total of 50,000 shares of the company's common stock on February 25 and 26, 2026.
The sales were executed pursuant to a pre-arranged 10b5-1 trading plan, indicating they were planned in advance and not based on insider knowledge.
The reporting person continues to hold a significant position of 154,657 shares, suggesting he maintains a substantial stake in the company.

Want the newest filings?

This analysis covers the filing from 2026-02-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-02-17

The reporting person, who is a director of Climb Bio, Inc., has sold a total of 100,000 shares of the company's common stock over the past two trading days. This represents a significant reduction in their beneficial ownership position.
The shares were sold pursuant to a pre-arranged 10b5-1 trading plan, which suggests that the sales were not driven by immediate concerns or insider knowledge.
The selling prices for the shares ranged from $5.22 to $6.12 per share, which appears to be in line with the company's current market valuation.

Filed: 2026-01-08

Cindy Driscoll, the Senior Vice President of Finance at Climb Bio, Inc., has been granted a stock option to acquire 100,000 shares of the company's common stock. This suggests potential insider confidence in the company's future performance.
The stock option has an exercise price of $3.81 per share and a 10-year expiration period, with the shares vesting over a 4-year period. This indicates a long-term incentive structure for the executive.
The filing indicates that the transaction was made pursuant to a written plan, which may suggest a pre-determined trading strategy that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Filed: 2026-01-08

Susan Altschuller, the Chief Financial Officer of Climb Bio, Inc., was granted a stock option to acquire 142,500 shares of the company's common stock on January 6, 2026.
The stock option has an exercise price of $3.81 and is scheduled to vest over a 4-year period, with 25% vesting on the first anniversary and the remaining shares vesting monthly thereafter.
This stock option grant suggests that the company is incentivizing its key executive to remain with the company and contribute to its long-term growth and success.

Filed: 2026-01-08

Megan Wilson Perrin, the Chief Business Officer of Climb Bio, Inc., has been granted 300,000 stock options with an exercise price of $3.81 and a 10-year expiration date.
The options are subject to a 4-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the next 36 months.
This stock option grant suggests that the company is incentivizing the executive team to drive long-term growth and value creation for shareholders.

Filed: 2026-01-08

Aoife Brennan, the President and CEO of Climb Bio, Inc., has been granted 700,000 stock options with an exercise price of $3.81 per share. This indicates that the company is incentivizing its top leadership to drive the company's long-term growth and success.
The stock options granted to Aoife Brennan are scheduled to vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments. This aligns the CEO's interests with those of the company's shareholders.
The fact that this stock option grant is being reported on a Form 4 filing suggests that Climb Bio, Inc. is a publicly-traded company, and the reporting of insider transactions is a regulatory requirement that provides transparency for investors.

Filed: 2026-01-07

RA Capital Management, L.P. and its affiliates have a significant ownership stake in Climb Bio, Inc., collectively owning over 75% of the outstanding shares.
Insiders at RA Capital Management, including Peter Kolchinsky and Rajeev Shah, reported purchasing additional shares of Climb Bio, further increasing their ownership position.
The large insider ownership and recent purchases suggest the insiders are confident in Climb Bio's prospects and see potential upside in the company's stock.

Other reports for Climb Bio, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.